Attend PACK EXPO – this year’s can’t-miss event in Chicago, Oct 23-26.
Discover solutions from 2,000+ exhibitors to advance your operations and network with colleagues at PACK EXPO International.

GlaxoSmithKline to open new vaccine plant in France

To meet the growing demand for pediatric and adult vaccines, GSK is investing more than 500 million euros in a vaccine manufacturing plant to increase production in formulation, filling, freeze-drying, and packaging.

The facility, located in St. Amand-Les Eaux, will contribute to the production of a Cervarix, a candidate vaccine for the prevention of cervical cancer. The company is waiting for results of a Phase III clinical trial before it files Cervarix in the U.S. market.

GSK's new meningitis vaccines will also be manufactured at this site as well as a new flu vaccine to protect against seasonal influenza and a pediatric vaccine to protect against streptococcus pneumonia.

The new site will house a freeze-drying plant, which will transform vaccines from a liquid to a solid powder. This operation is used to enhance the shelf life and stability of a number of GSK's vaccines. The site will also be equipped with a liquid plant for filling syringes and vials, a packing plant and warehouse, a power plant, and quality control laboratories. The facility is expected to open in 2011.
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub